Gut

Four-protein score better predicts death in UK Biobank

Researchers validated a four-protein score in an observational cohort of 115,971 people, comparing its predictions with established noninvasive scores.

Paper by Luis Anibal Diambra, Silvia C. Sookoian, Carlos Jose Pirola · Consejo Nacional de Investigaciones Científicas y Técnicas

Our read

Biomarkers
Studied:
Cohort study of 115,971 UK Biobank participants, more than 15 years
What changed:
The four-protein score predicted death from any cause better than established noninvasive scores
The catch:
The abstract does not quantify improvement in mortality prediction over existing scores
Why it’s aging research:
It measures an outcome that worsens with age.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Researchers analyzed 48,806 UK Biobank participants with MRI measurements of liver fat in an observational study with more than 15 years of follow-up. They used statistical grouping to identify patterns of metabolic dysfunction-associated steatotic liver disease, a condition involving liver fat and metabolic problems. These patterns revealed marked differences between sexes in disease severity and identified groups at higher risk of death.

Protein profiling led to a four-protein score. In an expanded cohort of 115,971 participants, with or without liver-fat MRI data, the score predicted death from any cause better than established noninvasive scores. A statistical analysis estimated that the score’s proteins accounted for 10–20% of the association between participants’ disease-pattern groups and mortality.

Why it matters

The work addresses why people with metabolic liver disease have different long-term survival prospects, looking beyond measures focused on the liver.

Caveats

The observational design cannot establish that the proteins caused differences in survival. The abstract does not quantify how much better the score predicted mortality than existing scores.

Comments

Be the first to comment.